

**ASIC Approval for Extension to Hold 2024 Annual General Meeting**

**HeraMED Limited (ASX:HMD)** ('HeraMED' or the 'Company') announces that in accordance with section 250P of the *Corporations Act 2001* ('Act'), Australian Securities and Investment Commission (ASIC) has granted an extension of time to hold its Annual General Meeting (AGM) to 20 June 2024.

At the time of the statutory deadline to release the Company's AGM Notice of Meeting to shareholders (s249HA), the Company was not in a position to include certain resolutions relating to proposed financing arrangements with third parties and the appointment of a new director filling a casual vacancy. Accordingly, ASIC has granted an extension of time which the Company is required to hold the AGM to 20 June 2024, providing shareholders the opportunity to consider and vote on matters critical to the future of the Company at a single shareholders meeting.

The AGM Notice of Meeting released on 30 April 2024 will be superseded by an updated Notice of Meeting. Details of the time and venue for the revised AGM will be advised in a formal Notice of Meeting which is expected to be announced and sent to shareholders shortly.

For any questions in relation to the extension of time to hold its AGM for the financial year ending 31 December 2023 please contact CFO & Company Secretary, Cameron Jones.

This announcement has been authorised by the Board of HeraMED Limited

-ENDS-

**.CEO**

Anoushka Gungadin

T: +61 431 131 649

E: [anoushka@hera-med.com](mailto:anoushka@hera-med.com)

**CFO & Company Secretary**

Cameron Jones

T: +61 400 086 399

E: [cameron.jones@bio101.com](mailto:cameron.jones@bio101.com)

**Investor Relations**

Tim Chapman

T: +61 419 897 062

E: [tchapman@claritycap.com.au](mailto:tchapman@claritycap.com.au)

**About HeraMED Limited (ASX:HMD):**

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.